

Boehringer  
Ingelheim

Revision ..... 3  
Operator ..... hal  
Date ..... 10Jan11  
Art # ..... 10423-02  
Item # ..... 410424-01  
Product ..... Naramune-2

Type/Size ..... Tray / 25x1mL  
Template # ..... 306  
Dimensions .... 3" x 8-1/2"  
File Path ..... V1/BI Labeling  
PDF ..... 12Jan11 hal  
Rev Level ..... 02

BLACK

PMS 1375

PMS 187

SEPARATIONS  
CHECKED BY:  
hal 06Jan11

TOP

Naramune-2™

Serial No.:  
Exp. Date:

**Storage:** Store out of direct sunlight at a temperature between 35-45°F (2-7°C).

**Preservative:** Neomycin.

**Disposal:** Burn containers and all unused contents.

See backside for Instructions and Precautions.



## Canine Parainfluenza- Bordetella Bronchiseptica Vaccine

Modified Live Virus  
Avirulent Live Culture

**Naramune-2™**  
For Intranasal Use in Dogs Only

Varied Dose Volume  
This package contains  
25 (1 dose) vials of dry vaccine,  
25 (1 mL) vials of sterile diluent  
and 25 nasal applicator tips.

Boehringer Ingelheim Vetmedica, Inc.  
St. Joseph, Missouri 64506 U.S.A.  
U.S. Veterinary License No. 124  
Code 110-475



Boehringer  
Ingelheim

Naramune-2™



10101  
10423-02

**Description and General Information:** Naramune-2™ Canine Parainfluenza Vaccine, Modified Live Virus, Bordetella Bronchiseptica Vaccine, Avirulent Live Culture is designed to be administered intranasally for convenient, rapid prevention of Canine Upper Respiratory Infection (Canine Cough). Both of these organisms are widespread, common etiologic agents of this syndrome which appears as a mild, self-limiting disease involving the trachea and bronchi of dogs of any age. It spreads rapidly among dogs that are closely confined as in hospitals, kennels and pet stores. The disease is highly contagious and is transmitted via the airborne route.

Both of the organisms in Naramune-2 are avirulent so that they can be safely administered intranasally with little or no symptoms of disease. By instilling these organisms into the nasal passages, it becomes possible for these agents to infect target cells of the nasal-pharyngeal region, mimicking the pathogenesis of natural field infection. A very small percentage of dogs may show sneezing, coughing or nasal discharge for 3-10 days following vaccination. While these are usually temporary symptoms, anti-bacterial therapy may be indicated.

**Indications:** For vaccination of healthy, susceptible dogs and puppies against Canine Upper Respiratory Infection (Canine Cough) caused by canine parainfluenza and *Bordetella bronchiseptica*. Field studies

support the safety of Naramune-2 when administered to puppies as young as 3 weeks of age.

**Rehydration:** Rehydrate to desired dose volume with accompanying sterile diluent. For 0.5 mL dose, reconstitute with 0.5 mL diluent. For 1 mL dose, reconstitute with 1 mL diluent. Shake well and use immediately.

**Dosage and Administration:** Using aseptic technique, administer entire dose intranasally. Use enclosed applicator tip on hub of syringe in place of syringe needle. Apply new nasal applicator tip for each dog vaccinated. Do not vaccinate puppies under 3 weeks of age. Puppies vaccinated between 3 and 6 weeks of age should be revaccinated at 6 weeks of age. Annual revaccination is recommended.

**Precautions:** For intranasal use in dogs only; do not vaccinate dogs parenterally. Store out of direct sunlight at a temperature between 35-45°F (2-7°C). Use entire contents when first opened. Burn containers and all unused contents. Anaphylactoid reactions may occur.

**Antidote:** Epinephrine.